VitalConnect’s Cardiac Monitoring “VitalPatch” Receives Emergency FDA Approval
May 19, 2020
The VitalPatch is a wearable biosensor that will assist clinicians in monitoring COVID-19 patients.
By PR Newswire
The VitalPatch is a wearable biosensor that will assist clinicians in monitoring COVID-19 patients. The biosensor provides valuable vital sign and cardiac monitoring information that will help save lives.
"COVID-19 presents a myriad of symptoms and clinicians need access to medical devices that allow them to monitor and manage those symptoms in real-time in order to create the most appropriate treatment plans for each individual," said Dr. Joe Roberson, Chief Medical Officer of VitalConnect. "The enhancement of the VitalPatch receiving Emergency Use Authorization for QT-interval detection will enable this platform to further support clinicians who are on the frontlines of treating this virus."
